Columbia Wanger Asset Management’s Haemonetics HAE Stock Holding History

Columbia Wanger Asset Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$52.7M	Buy	907,049 +145,722	+19%	+$7.67M	0.79%	33
2017 Q3	$34.2M	Sell	761,327 -16,165	-2%	-$672K	0.51%	87
2017 Q2	$30.7M	Buy	777,492 +191,202	+33%	+$7.85M	0.44%	103
2017 Q1	$23.8M	Buy	+586,290	New	+$22.9M	0.33%	135
2013 Q4	–	Sell	-456,120	Closed	-$18.2M	–	306
2013 Q3	$18.2M	Sell	456,120 -713,880	-61%	-$30M	0.07%	253
2013 Q2	$48.4M	Buy	+1,170,000	New	+$47.4M	0.21%	161

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Columbia Wanger Asset Management's HAE Position: Q4 2017 in Review

Columbia Wanger Asset Management increased its Haemonetics (HAE) stake by 19% in Q4 2017, buying an estimated $7.67M and bringing the position to 907,049 shares worth $52.7M. The position accounts for 0.79% of the portfolio, ranked #33.

Columbia Wanger Asset Management first reported a position in HAE in Q2 2013 and has held it in 6 quarters since. 246 funds tracked by Wall St. Rank hold HAE as of Q4 2017.

Columbia Wanger Asset Management held 907,049 shares of Haemonetics worth $52.7M as of Q4 2017.
Columbia Wanger Asset Management bought 145,722 Haemonetics shares in Q4 2017, an estimated $7.67M.
Haemonetics made up 0.79% of Columbia Wanger Asset Management's portfolio in Q4 2017, its #33 holding.
Columbia Wanger Asset Management first reported a position in Haemonetics in Q2 2013 and has held it in 6 quarters since.
246 funds tracked by Wall St. Rank held Haemonetics as of Q4 2017.

Based on Columbia Wanger Asset Management's 13F filing for Q4 2017, filed 13 Feb 2018.